Fluocinolone acetonide 0.025% / Neomycin 0.5% cream
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Yellow Card
Report side effects (MHRA)
Drug safety updates
MHRA alerts for Fluocinolone acetonide + Neomycin
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
Search EudraVigilance database
Browse substances A–Z in the European adverse reaction database
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 15 · Randomised trials: 5 · 2007–2025
Showing the 50 most relevant studies, sorted by most relevant.
Weiping Hu, Liyang Ni, Huangfang Ying, et al.
Pakistan Journal of Medical Sciences, 2025
ABSTRACT Background & Objective: Several diabetic macular edema (DME) patients are resistant to anti-vascular endothelial growth factors (VEGF) injections and are treated with corticosteroid implants. Dexamethasone implants (DEXI) are popular, but fluocinolone acetonide implants (FACI) are being used as third-line DME therapy, given their convenience and prolonged action. The efficacy of FACI in patients previously treated with DEXI remains understudied. We collated evidence from single-arm studies examining the efficacy and safety of FACI in DME patients treated with DEXI. Methodology: We explored the websites of Embase, PubMed, PubMed CENTRAL, Web of Science, and Scopus up to January 15, 2025. Pre and post-FACI best-corrected visual acuity (BCVA), central retinal thickness (CRT), and intraocular pressure (IOP) were compared. Results: Eight studies with 365 eyes were included. Meta-analysis showed that use of FACI was associated with statistically significant improvement in BCVA (letters) at three months (MD: 5.40 95% CI: 0.13, 10.67 I2= 78%) but not at six months (MD: 5.43 95% CI: 1.79, 12.64 I2=86%), and 12 months (MD: 3.39 95% CI: 3.12, 9.91 I>2=84%). The pooled analysis indicated a statistically significant reduction in CRT after administration of FACI at 3 months (MD: 118.11 95% CI: 211.62, -24.61 I2=93%), six months (MD: 121.79 95% CI: 212.35, -31.24 I2=94%), and 12 months (MD: 108.33 95% CI: 175.47, -41.2 I2=92%). No significant change in IOP was noted at all follow-up intervals. Conclusions: Use of FACI in patients previously treated with DEXI results in anatomical improvement but may be associated with limited visual gain. The use of FACI seems safe without significant change in IOP. Registration: PROSPERO CRD42025635691.
Abstract licence: CC BY
Suji Yeo, Yoo-Ri Chung, Ji Hun Song, et al.
Biomedicines, 2025
M. Fallico, A. Maugeri, A. Lotery, et al.
Scientific Reports, 2021
Lara Buhl, Valerie Schmelter, B. Schworm, et al.
Ocular Immunology and Inflammation, 2023
Honghua Hu, Pengfei Zhou, Hongliang Yao, et al.
Journal of Cosmetic Dermatology, 2025
Treatment with fluocinolone acetonide, hydroquinone, and tretinoin cream is the gold standard for melasma; however, the effects of this treatment in the Chinese population remain unclear. Due to the differences between Chinese and Caucasian subjects, further clinical trials in Chinese patients with melasma are needed.
Abstract licence: CC BY
Archives of Ophthalmology, 2008
Lara Buhl, S. Thurau, C. Kern
Graefe's Archive for Clinical and Experimental Ophthalmology, 2022
L. Chu, A. Acosta, H. Aazami, et al.
JAMA Network Open, 2022
- Otitis Externa
- Earache
- Acute Disease
Uwe Pleyer, C. Pavesio, E. Miserocchi, et al.
Journal of Ophthalmic Inflammation and Infection, 2024
Yusuf Mushtaq, Maryam Mushtaq, Z. Gatzioufas, et al.
Drug Design, Development and Therapy, 2023
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
1.3-1.7 hours
Mechanism
Fluocinolone acetonide is a corticosteroid and thus, it can be inferred that it…
Food interactions
None known
Human targets
7 targets
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
12 months
[L4686]
…
Half-life
1.3-1.7 hours
[A39536]
Protein binding
Volume of distribution
Metabolism
Elimination
Clearance
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
-In dermatology, it is extensively used for the relief of inflammatory dermatosis, dermatitis, psoriasis, hypertrophic tissues, keloid tissues and atopic dermatitis.[F1955]
-It has been used in shampoo products as a low to medium potency corticosteroid for the treatment of seborrheic dermatitis of the scalp.
[L4682]
-In ear drops, it is used as a low to medium potency corticosteroid for the treatment of chronic eczematous external otitis in adults and pediatric patients 2 years and older.
[L4683]
-As an intravitreal implant, it is indicated for the treatment of diabetic macular edema with patients that have been previously treated with a course of corticosteroids and no clinically significant rise in intraocular pressure.
[L4684]
-Fluocinolone acetonide was announced on October 15, 2018 to be FDA approved for the treatment of chronic non-infectious uveitis affecting the posterior segment of the eye.
[L4685]
-Some reports have indicated the use of fluocinolone acetonide as a vasoprotective agent and for its use in the treatment of first-degree hemorrhoids.
[A39532]
Known interactions with other medicines. Always consult a healthcare professional.
Showing 50 of 1538 interactions
Some reports have indicated that fluocinolone acetonide presents a high binding affinity for the glucocorticoid receptor. After binding the receptor, the newly formed receptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements in the promoter region of the target genes.[A16592] This effect promotes the induction of phospholipase A2 inhibitory proteins (lipocortins). Through this mechanism of action, it is thought that fluocinolone induces mainly one of the lipocortins, annexin 1, which will later mediate the synthesis of inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of arachidonic acid which is the precursor of all these inflammatory mediators. Hence, the induction of these proteins will prevent the release of arachidonic acid by phospholipase A2.[F1957]
For its ophthalmic indications, fluocinolone acetonide is administered as intravitreal micro-insert. This preparation was observed in clinical trials to reduce the recurrence of uveitis flares by 2 fold when compared with the non treated patients even after six months after initial administration. As well the intraocular pressure seemed to increase slightly with the presence of the fluocinolone implant but it is important to monitor intraocular pressure.[L4685]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L4686]
The concentration of fluocinolone acetonide are generally higher in the vitreous and retina with a little dispersion to the aqueous humor.[T359]
There are reports indicating that topical administration of fluocinolone acetonide produces a percutaneous absorption which is determined by the vehicle, integrity of the epidermal barrier and the use of occlusive dressing.[F1956]
Independently of the route of administration, the systemic absorption of fluocinolone acetonide is below 0.1 ng/ml which indicates that the systemic distribution is very minimal and the effect of fluocinolone is mainly local.
[A39533]
[A39536]
Proteins and enzymes this drug interacts with in the body
PMID:27120390 PMID:37478846
Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors .
PMID:28139699
Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Involved in chromatin remodeling .
PMID:9590696
Plays a role in rapid mRNA degradation by binding to the 5' UTR of target mRNAs and interacting with PNRC2 in a ligand-dependent manner which recruits the RNA helicase UPF1 and the mRNA-decapping enzyme DCP1A, leading to RNA decay .
PMID:25775514
Could act as a coactivator for STAT5-dependent transcription upon growth hormone (GH) stimulation and could reveal an essential role of hepatic GR in the control of body growth (By similarity)
PMID:8425544
Plays a role in glucocorticoid-mediated down-regulation of the early phase of the inflammatory response (By similarity). Contributes to the adaptive immune response by enhancing signaling cascades that are triggered by T-cell activation, regulates differentiation and proliferation of activated T-cells .
PMID:17008549
Promotes the differentiation of T-cells into Th1 cells and negatively regulates differentiation into Th2 cells .
PMID:17008549
Has no effect on unstimulated T cells .
PMID:17008549
Negatively regulates hormone exocytosis via activation of the formyl peptide receptors and reorganization of the actin cytoskeleton .
PMID:19625660
Has high affinity for Ca(2+) and can bind up to eight Ca(2+) ions (By similarity).
Displays Ca(2+)-dependent binding to phospholipid membranes .
PMID:2532504 PMID:8557678
Plays a role in the formation of phagocytic cups and phagosomes. Plays a role in phagocytosis by mediating the Ca(2+)-dependent interaction between phagosomes and the actin cytoskeleton (By similarity)
Inhibits PCSK9-enhanced LDLR degradation, probably reduces PCSK9 protein levels via a translational mechanism but also competes with LDLR for binding with PCSK9 .
PMID:18799458 PMID:22848640 PMID:24808179
Binds to endosomes damaged by phagocytosis of particulate wear debris and participates in endosomal membrane stabilization, thereby limiting NLRP3 inflammasome activation (By similarity). Required for endothelial cell surface plasmin generation and may support fibrinolytic surveillance and neoangiogenesis (By similarity)
Enzymes involved in drug metabolism — important for understanding drug interactions
Proteins that carry this drug through the body
ATC S01CA10
ATC D07BC02
ATC S02BA08
ATC C05AA10
ATC S01BA15
ATC D07AC04
ATC S02CA05
ATC D07CC02
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
DrugBank citations
If you use DrugBank data in your research, please cite:
- DrugBank 6.02024Recommended citationKnox C., Wilson M., Klinger C.M., et alDrugBank 6.0: the DrugBank Knowledgebase for 2024Nucleic Acids Res. 2024 Jan 552(D1):D1265-D1275
- DrugBank 5.02018Wishart D.S., Feunang Y.D., Guo A.C., et alDrugBank 5.0: a major update to the DrugBank database for 2018Nucleic Acids Res. 2017 Nov 846(D1):D1074-D1082
- DrugBank 4.02014Law V., Knox C., Djoumbou Y., et alDrugBank 4.0: shedding new light on drug metabolismNucleic Acids Res. 2014 Jan 142(1):D1091-7
- DrugBank 3.02011Knox C., Law V., Jewison T., et alDrugBank 3.0: a comprehensive resource for 'omics' research on drugsNucleic Acids Res. 2011 Jan39(Database issue):D1035-41
- DrugBank 2.02008Wishart D.S., Knox C., Guo A.C., et alDrugBank: a knowledgebase for drugs, drug actions and drug targets.Nucleic Acids Research2008 Jan36(Database issue):D901-6
- DrugBank 1.02006Wishart D.S., Knox C., Guo A.C., et alDrugBank: a comprehensive resource for in silico drug discovery and exploration.Nucleic Acids Research2006 Jan 134(Database issue):D668-72